Clinical trial NCT05945329: Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
Official title: A Prospective, Randomized, Controlled, Multi-Center Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Capsular Contracture Associated With Breast Implant
Capsular Contracture Grade III
Capsular Contracture Grade IV
Lead sponsor: C. R. Bard
Sponsor class: INDUSTRY
First posted: 2023-07-14
Enrollment: 250
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Multi-center, prospective, randomized
Primary purpose: TREATMENT

Brief summary: Prospective, randomized, controlled study to assess the safety and effectiveness of GalaFLEX LITE™ Scaffold in revision surgery for reduction of capsular contracture recurrence and/or malposition in implant-based breast augmentation patients versus patients undergoing conventional revision surgery with no supportive matrix or acellular dermal matrix (ADM). Subjects will be randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care (no ADM or matrix placement). This study is designed using an adaptive approach. The number of the treated breasts will range between 250 and 530.

Detailed description: Capsular contracture is the number one complication leading to revision surgery after breast augmentation(2-4) which has been commonly cited as impacting 10 to 20% of all breast augmentation patients.(5-10) A prospective, randomized controlled study of patients presenting with Baker grade III or IV capsular contracture will be undertaken to investigate the ability of P4HB (specifically GalaFLEX LITE™ Scaffold) to reduce the recurrence of clinically significant CC and/or malposition requiring surgical correction. The primary endpoint is a composite of capsular contracture recurrence and/or breast implant malposition recommended for surgery OR breast infections requiring oral or IV antibiotic treatment within 90 days of surgery and/or peri-implant fluid collection needing a drainage procedure within 10-90 days of surgery.

Eligibility criteria: Inclusion Criteria:

1. Genetically female ≥22 and ≤66 years of age;
2. Breast augmentation subject with capsular contracture (Baker grade III or IV);
3. Desired a new implant with no more than a 25% increase in implant size (not to exceed a volume increase greater than 150cc compared to the existing implant);
4. Planned revision approach via inframammary fold (IMF) incision;
5. Willing and able to comply with the study procedures including the 2-year follow-up visit;
6. Lives within 3 hours driving distance from the investigator site; and,
7. Provision of signed and dated informed consent form.

Exclusion Criteria:

1. BMI \<18 or \>35
2. Existing and/or replacement implant size \> 800 cc
3. Had ≥2 capsular contracture revisions on the breast(s) intended for treatment
4. Has an extra-capsular rupture (breast implant silicone gel or saline has leaked outside of the capsule) in breast(s) intended for treatment
5. Has prior use of a matrix (synthetic or biologic) in the breast(s) intended for treatment.
6. Abnormal findings on diagnostic imaging within 1-year of study enrollment (mammogram for patients ≥35 years old; MRI for patients \<35 years old or breast ultrasound if MRI is contraindicated)
7. Has symptoms consistent with Breast Implant Illness (BII)Systemic Symptoms Associated with Breast Implants (SSBI)
8. Infection present in the breast (day of surgery exclusions are noted in Section 5.3)
9. Current or recent breast feeding (within 3-months or enrollment) or history of mastitis within the 6-months prior to enrollment
10. Prior or current diagnosis of breast cancer
11. Has a mass that was palpated and has not been determined benign via acceptable imaging (MRI) or biopsy results
12. Has undergone prior chest radiation treatment
13. Has received chemotherapy within the last 12 months
14. Current or recent (within 1-year of enrollment) alcohol/substance abuse
15. Current or recent (within 4-weeks of enrollment) nicotine user (includes cigarettes, vaping, patches, gum, etc.)
16. History of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) or Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC)
17. Planned use of another type of matrix (such as ADM) in addition to GalaFLEX LITE™
18. Current or planned use of medical (e.g. Singulair), physical (e.g. massage), or device-assisted (e.g. mechanical/thermal ultrasound) tools to manage the breast capsule(s)
19. Any medical condition that, in the opinion of the investigator, may be associated with unduly high risk of intra- or post-operative complications (e.g., insulin-dependent diabetes, autoimmune disease, connective tissue disorder, chronic lung or severe cardiovascular disease)
20. Concurrent or planned (within the 2-year follow-up time period) elective cosmetic breast operation to the treated breast (e.g., autologous fat transfer, mastopexy, or implant size changes)
21. Currently enrolled or has plans to enroll in another clinical study that would interfere with this study, unless it is a retrospective or observational study
22. Is pregnant or plans to become pregnant during the study period
23. Known allergy to tetracycline hydrochloride and kanamycin sulfate
24. Any condition that, in the Investigator's opinion, would preclude the use of the study device, interfere with the evaluation of the device or breast related outcomes
25. Subject will not remain under the care of the investigator for all plastic surgery procedures while enrolled in the study
26. Actively using immunosuppressants such as oral steroids or biological therapies (inhalers or topical steroids are permitted)
27. Confirmed diagnosis of the following rheumatic diseases or syndromes: systemic lupus erythematosus, Sjorgren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome
28. Has, in the investigator's opinion, a mental illness or disability that would preclude their participation in the study
29. Subject has an implant that was never commercially available in the United States (had their breast augmentation in another country)
30. Has been implanted with any silicone implant other than breast implants
31. Is taking any drugs that would interfere with blood clotting or might result in elevated risk of significant postoperative complications
32. Works for Sponsor or any of their subsidiaries, the study surgeon, or is helping to conduct the study or are directly related to anyone that works for BD or any of their subsidiaries or the study surgeons. -

Primary outcomes:
measure: Effectiveness of GalaFLEX LITE™ Scaffold for the stabilization of the implant pocket
timeFrame: 24-months after index surgery
Secondary outcomes:
measure: Patient quality of life and satisfaction (12-month)
timeFrame: 12-months after index surgery
measure: Patient quality of life and satisfaction
timeFrame: 24-months after index surgery
measure: Safety of GalaFLEX LITE™ Scaffold for the stabilization of the implant pocket, reduction of capsular contracture recurrence, and/or malposition
timeFrame: 90 days
Other outcomes:
measure: Device or procedure related adverse events
timeFrame: 24-months after index surgery
Locations:
city: Beverly Hills
country: United States
facility: The Practice Plastic Surgery
state: California
city: Newport Beach
country: United States
facility: Newport Plastic and Reconstructive Surgery Associates
state: California
city: Boca Raton
country: United States
facility: Sanctuary Plastic Surgery
state: Florida
city: Saint Petersburg
country: United States
facility: Billington Plastic Surgery
state: Florida
city: Indianapolis
country: United States
facility: Meridian Plastic Surgery Center
state: Indiana
city: New York
country: United States
facility: Plastic Surgery Institute of New York
state: New York
city: Huntersville
country: United States
facility: H/K/B Surgery
state: North Carolina
city: Tulsa
country: United States
facility: Essential Medical Research
state: Oklahoma
city: Draper
country: United States
facility: The Plastics Clinic
state: Utah
Study officials:
References: